What happened to anti-CD33 therapy for acute myeloid leukemia? - Wikidata - wikimedia - TriplyDB

What happened to anti-CD33 therapy for acute myeloid leukemia?

What happened to anti-CD33 therapy for acute myeloid leukemia?

http://www.wikidata.org/entity/Q37959880

about

Theranostic applications of antibodies in oncology.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia.The myth of the second remission of acute leukemia in the adult.Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.Involvement of calreticulin in cell proliferation, invasion and differentiation in diallyl disulfide-treated HL-60 cells.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma.Orofacial adverse effects of biological agents.Immunotherapy in acute myeloid leukemia.KCa 3.1-a microglial target ready for drug repurposing?Antibody-Based Treatment of Acute Myeloid Leukemia.The progress and current status of immunotherapy in acute myeloid leukemia.

P2860

Q27693293-4CBC5FE8-E234-4F6A-B80E-A457EE6B5815 Q33903030-7B9954CC-51A8-400E-83BB-9A4D31BD8450 Q35726245-B2E242FC-F830-4571-8CA3-9BCAB11CB405 Q35818377-3B275631-4513-4440-ADBC-171D6C4C0AB3 Q35837399-1F4EC2FD-758D-45D6-9C9D-78A629F7CA7C Q36619678-90DBC73A-099C-4A72-B7EE-27B1D270929D Q36655884-388FD0AD-6C73-4072-A0B0-56B414BC81BC Q36814661-BE037AED-4594-475D-B5F4-9F7141BB4823 Q36989586-896BA462-4620-46F9-96DB-845A43665E27 Q36996975-54865D15-07E7-4422-AFD2-3AD6CA97F746 Q37204261-2BA2D5C1-871E-422C-B182-2F1F946FB80F Q37643136-EBAECD1A-1CCE-49D3-B93C-6B1C1C8B6369 Q37738158-F0A9CCE0-84E5-433E-844D-795C82B709FA Q38213692-0BC8AF70-65D9-4049-BFD8-0CEAC84FF4BC Q38533606-88A3C790-431F-49F2-B136-881B4A63D90D Q38819263-C7F7B155-82A6-4D0E-90EA-301C53772C5C Q38979277-9E88C958-2B24-46C2-B81D-3B9E329DE949 Q47590707-EC136131-8D3A-4ADC-BC9B-DC06F2C897E4

P2860

What happened to anti-CD33 therapy for acute myeloid leukemia?

http://www.wikidata.org/entity/Q37959880

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

What happened to anti-CD33 therapy for acute myeloid leukemia?

@en

What happened to anti-CD33 therapy for acute myeloid leukemia?

@nl

type

label

What happened to anti-CD33 therapy for acute myeloid leukemia?

@en

What happened to anti-CD33 therapy for acute myeloid leukemia?

@nl

prefLabel

What happened to anti-CD33 therapy for acute myeloid leukemia?

@en

What happened to anti-CD33 therapy for acute myeloid leukemia?

@nl

P1433

Q37959880-6AE2758D-1410-4C9A-AD90-67DCB286841F

P1476

Q37959880-99C3EE4A-E441-4B67-B6D5-EFCFA33281A5

P2093

Q37959880-394E4D99-6F34-4C65-B285-97F57C85E366

P2860

Q37959880-02DD44E5-85C6-4654-ACE6-00418075F52C

Q37959880-051A93D7-78CC-40F1-8FCE-0F19A8D38368

Q37959880-1A8B0539-BE2E-497D-972F-C1A030ECC02E

Q37959880-2A5F48E9-A50E-4680-8C5C-3CB5A0E7ACA6

Q37959880-2D137EC8-2835-43C6-A904-A384E41A187D

Q37959880-30C674CB-B2C2-43D9-BC4B-DA5B03B6D748

Q37959880-396A2275-6D32-40EF-9883-71B39DA0AA37

Q37959880-399B6D31-ADCB-4547-9224-35C958729CAF

Q37959880-49E2491A-2A5E-47F5-90CF-BE05C1690CCD

Q37959880-72611C2C-44E0-45D3-9636-F2DB429953DE

P2888

Q37959880-96812F67-0594-4843-A8F9-8741A25C1009

P304

Q37959880-3AADC38C-1A55-4B05-9E97-8BCB2FD4F01C

P31

Q37959880-A75E4DC1-0E78-4BF2-8C83-C7FD061C6BDB

P356

Q37959880-5064AD09-9064-43F3-BA9F-3C8E699A6184

P433

Q37959880-71E07FDD-3B7B-4B74-99EA-DB954F05F630

P478

Q37959880-C712E529-EFAF-4475-A2D4-F4D4A1F8874D

P577

Q37959880-D0C98A14-300C-4965-AC6D-050F450E19F6

P698

Q37959880-D6D47D16-6F54-405A-ACB8-8794A2AE0489

P921

Q37959880-841BE8B6-EAED-4159-86FA-9EEA24E15F1D

P356

S11899-011-0103-0

P1433

Current hematologic malignancy reports

P1476

What happened to anti-CD33 therapy for acute myeloid leukemia?

@en

P2093

Joseph G Jurcic

http://www.w3.org/2001/XMLSchema#string

P2860

The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA

Tumor therapy with targeted atomic nanogenerators.

Engineered antibody Fc variants with enhanced effector function.

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

Heterogeneity of clonogenic cells in acute myeloblastic leukemia.

Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin

P2888

s11899-011-0103-0

P304

65-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-011-0103-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22109628

http://www.w3.org/2001/XMLSchema#string

P921